Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

FDA granted Fast Track designation to Lu AH69593, an oral orexin-2 receptor agonist, for treatment of narcolepsy. The designation supports accelerated development for a therapy targeting the orexin pathway central to wakefulness/sleep-wake regulation. This is a meaningful regulatory milestone that could improve clinical and commercial outlook for the program.

Analysis

FDA granted Fast Track designation to Lu AH69593, an oral orexin-2 receptor agonist, for treatment of narcolepsy. The designation supports accelerated development for a therapy targeting the orexin pathway central to wakefulness/sleep-wake regulation. This is a meaningful regulatory milestone that could improve clinical and commercial outlook for the program.